KALA
KALA BIO, Inc.
Set alert
0.17 USD -0.01 -5.48%
0.163 Day range 0.1832
0.1655 52-week range 66.50
- YTD
- -99.40%
- 1 year
- -99.56%
- Open
- 0.175
- Prev close
- 0.1751
- Mkt cap
- 3.20M
- Vol
- 246.11K
- Avg vol
- 1.51M
- EPS
- -10.71
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.163
- High
- 0.1832
- Forward P/E
- -0.90
- Beta
- -2.14
- Short ratio
- 1.91
- Inst. own
- 48.13%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 6.42
- 200-d avg
- 6.50
- 1y target
- 15.00
Key statistics
- Market cap
- 27.66M
- Enterprise value
- 15.27M
- Trailing P/E
- 0.00
- Forward P/E
- -0.90
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 2.21
- EPS (TTM)
- -11.67
- Beta
- -2.14
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -20.51M
- Total cash
- 54.20M
- Total debt
- 36.80M
- Return on equity
- -248.11%
- Shares outstanding
- 4.61M
- Short % of float
- 0.85%
- 50-day average
- 6.42
- 200-day average
- 6.50
Analyst view
Consensus: none
Price target (mean) 15.00
Ratings (0m) 2 2 buy · 0 hold · 0 sell
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -2.47.
Financials — quick view
KALA Revenue — quarterly 0
KALA Net income — quarterly -1.58M
KALA EPS — quarterly -21.32
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -2.43 | -1.93 | +0.50 | +20.58% |
| Aug 6, 2024 | Jun 1, 2024 | -4.41 | -3.16 | +1.25 | +28.34% |
| May 14, 2024 | Mar 1, 2024 | -2.89 | -4.20 | -1.31 | -45.33% |
| Mar 29, 2024 | Dec 1, 2023 | -3.62 | -3.18 | +0.44 | +12.15% |
| Nov 13, 2023 | Sep 1, 2023 | -2.15 | -3.41 | -1.26 | -58.60% |
| Aug 4, 2023 | Jun 1, 2023 | -3.19 | -4.36 | -1.17 | -36.68% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 19, 2024 | Oppenheimer | reit | Outperform | Outperform |
| May 17, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Apr 2, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Apr 1, 2024 | Oppenheimer | reit | Outperform | Outperform |
| Nov 17, 2023 | HC Wainwright & Co. | main | Buy | Buy |
About KALA BIO, Inc.
KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- kalarx.com
News
- 12 Health Care Stocks Moving In Friday's After-Market Session
- KALA BIO, Inc. (NASDAQ:KALA) Stock Short Interest Report for September
- KALA BIO (NASDAQ:KALA) Stock Falls 0.9% – Time to Sell?
- 12 Health Care Stocks Moving In Thursday's After-Market Session
- 12 Health Care Stocks Moving In Wednesday's After-Market Session
- Why FingerMotion Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
- KALA Bio (KALA) Shares Soar 57% After Hours: Here's Why
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- KALA Bio Inks Letter Of Intent To Acquire U.S.-Based Management Services Firm For ~$15M
- KALA Bio Signs Non-Binding LOI to Acquire Nationwide Telehealth Platform with Approximately $48 Million in Sales Since Inception
Your note
Sign in to keep a note on KALA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAZEMORE TODD M | President | Sale | Jun 25, 2024 | 22,385 |
| BLUMENKRANZ MARK S | Director | Stock Award(Grant) | Jun 10, 2024 | 182,821 |
| BRAZZELL ROMULUS KIM | Officer | Sale | Jun 25, 2024 | 83,982 |
| IWICKI MARK T. | Chief Executive Officer | Sale | Jun 25, 2024 | 263,755 |
| KHARABI DARIUS | Officer | Sale | Jun 25, 2024 | 59,728 |
| KOVEN ANDREW IAN | Director | Stock Award(Grant) | Jun 10, 2024 | 13,922 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Baker Bros. Advisors, LP | 19.33% | 891,335 | 5.35M | Sep 29, 2024 |
| SR One Capital Management, LP | 9.62% | 443,661 | 2.66M | Sep 29, 2024 |
| Adar1 Capital Management, LLC | 6.64% | 306,067 | 1.84M | Sep 29, 2024 |
| O'Connor, A Distinct Business Unit of UBS Asset Mgmt Americas (LLC) | 3.53% | 162,663 | 975.98K | Sep 29, 2024 |
| Millennium Management Llc | 3.05% | 140,731 | 844.39K | Sep 29, 2024 |
| Vanguard Group Inc | 1.16% | 53,570 | 321.42K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 0.57% | 26,442 | 158.65K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.57% | 26,296 | 157.78K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.45% | 20,825 | 124.95K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.18% | 8,351 | 50.11K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.11% | 4,997 | 29.98K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.03% | 1,482 | 8.89K | Oct 30, 2024 |